Its losses have been rising in recent years as has its share count -- a notable concern for investors. 10 stocks we like ...

If you are eyeing Recursion Pharmaceuticals and wondering whether now is the time to act, you are not alone. The stock just staged a remarkable run, up 20.8% over the past week and soaring 36.0% ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

It might look like this beaten-down AI-focused company is finally bouncing back, but don't be too quick to pull the trigger.